Annual CFI
-$467.10 M
-$290.00 M-163.75%
31 December 2023
Summary:
Neurocrine Biosciences annual cash flow from investing activities is currently -$467.10 million, with the most recent change of -$290.00 million (-163.75%) on 31 December 2023. During the last 3 years, it has fallen by -$471.20 million (-11492.68%). NBIX annual CFI is now -488.34% below its all-time high of $120.28 million, reached on 31 December 2006.NBIX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$24.70 M
+$52.90 M+187.59%
30 September 2024
Summary:
Neurocrine Biosciences quarterly cash flow from investing activities is currently $24.70 million, with the most recent change of +$52.90 million (+187.59%) on 30 September 2024. Over the past year, it has increased by +$122.00 million (+125.39%). NBIX quarterly CFI is now -73.55% below its all-time high of $93.40 million, reached on 30 June 2020.NBIX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$260.30 M
+$122.00 M+31.91%
30 September 2024
Summary:
Neurocrine Biosciences TTM cash flow from investing activities is currently -$260.30 million, with the most recent change of +$122.00 million (+31.91%) on 30 September 2024. Over the past year, it has increased by +$120.60 million (+31.66%). NBIX TTM CFI is now -316.41% below its all-time high of $120.28 million, reached on 31 December 2006.NBIX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBIX Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -163.8% | +125.4% | +31.7% |
| 3 y3 years | -10000.0% | +119.6% | +13.7% |
| 5 y5 years | -92.3% | +128.9% | -72.2% |
NBIX Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | <-9999.0% | at low | -21.3% | +112.2% | -588.6% | +45.8% |
| 5 y | 5 years | <-9999.0% | at low | -73.5% | +112.2% | -865.6% | +45.8% |
| alltime | all time | -488.3% | at low | -73.5% | +111.6% | -316.4% | +45.8% |
Neurocrine Biosciences Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $24.70 M(-187.6%) | -$260.30 M(-31.9%) |
| June 2024 | - | -$28.20 M(-48.7%) | -$382.30 M(-20.4%) |
| Mar 2024 | - | -$55.00 M(-72.7%) | -$480.00 M(+2.8%) |
| Dec 2023 | -$467.10 M(+163.7%) | -$201.80 M(+107.4%) | -$467.10 M(+22.6%) |
| Sept 2023 | - | -$97.30 M(-22.7%) | -$380.90 M(+10.4%) |
| June 2023 | - | -$125.90 M(+199.0%) | -$344.90 M(+83.8%) |
| Mar 2023 | - | -$42.10 M(-63.6%) | -$187.60 M(+5.9%) |
| Dec 2022 | -$177.10 M(+36.0%) | -$115.60 M(+88.6%) | -$177.10 M(+368.5%) |
| Sept 2022 | - | -$61.30 M(-295.2%) | -$37.80 M(-63.2%) |
| June 2022 | - | $31.40 M(-199.4%) | -$102.70 M(-54.3%) |
| Mar 2022 | - | -$31.60 M(-233.3%) | -$224.90 M(+72.7%) |
| Dec 2021 | -$130.20 M(-3275.6%) | $23.70 M(-118.8%) | -$130.20 M(-56.8%) |
| Sept 2021 | - | -$126.20 M(+39.0%) | -$301.60 M(+100.8%) |
| June 2021 | - | -$90.80 M(-243.9%) | -$150.20 M(-541.8%) |
| Mar 2021 | - | $63.10 M(-142.7%) | $34.00 M(+729.3%) |
| Dec 2020 | $4.10 M(-101.9%) | -$147.70 M(-686.1%) | $4.10 M(-128.5%) |
| Sept 2020 | - | $25.20 M(-73.0%) | -$14.40 M(-88.5%) |
| June 2020 | - | $93.40 M(+181.3%) | -$125.20 M(-42.8%) |
| Mar 2020 | - | $33.20 M(-120.0%) | -$218.90 M(+3.7%) |
| Dec 2019 | -$211.10 M(-13.1%) | -$166.20 M(+94.2%) | -$211.10 M(+39.7%) |
| Sept 2019 | - | -$85.60 M(>+9900.0%) | -$151.14 M(+36.6%) |
| June 2019 | - | -$300.00 K(-100.7%) | -$110.64 M(-23.6%) |
| Mar 2019 | - | $41.00 M(-138.6%) | -$144.85 M(-40.4%) |
| Dec 2018 | -$242.90 M(-3.3%) | -$106.24 M(+135.6%) | -$242.90 M(+23.9%) |
| Sept 2018 | - | -$45.09 M(+30.7%) | -$196.05 M(+5.2%) |
| June 2018 | - | -$34.51 M(-39.5%) | -$186.35 M(-49.0%) |
| Mar 2018 | - | -$57.05 M(-3.9%) | -$365.15 M(+45.3%) |
| Dec 2017 | -$251.25 M(-322.4%) | -$59.39 M(+67.8%) | -$251.25 M(+42.2%) |
| Sept 2017 | - | -$35.39 M(-83.4%) | -$176.70 M(+80.1%) |
| June 2017 | - | -$213.31 M(-475.2%) | -$98.11 M(-198.6%) |
| Mar 2017 | - | $56.85 M(+275.0%) | $99.55 M(-11.9%) |
| Dec 2016 | $112.95 M(-157.7%) | $15.16 M(-64.9%) | $112.95 M(-5.8%) |
| Sept 2016 | - | $43.20 M(-375.9%) | $119.85 M(+316.3%) |
| June 2016 | - | -$15.66 M(-122.3%) | $28.79 M(-404.2%) |
| Mar 2016 | - | $70.25 M(+218.6%) | -$9.46 M(-95.2%) |
| Dec 2015 | -$195.81 M(+85.8%) | $22.05 M(-146.1%) | -$195.81 M(-3.2%) |
| Sept 2015 | - | -$47.86 M(-11.2%) | -$202.32 M(+33.8%) |
| June 2015 | - | -$53.91 M(-53.6%) | -$151.25 M(-2.9%) |
| Mar 2015 | - | -$116.09 M(-846.8%) | -$155.73 M(+47.8%) |
| Dec 2014 | -$105.37 M(-2073.1%) | $15.54 M(+383.4%) | -$105.37 M(+5.2%) |
| Sept 2014 | - | $3.22 M(-105.5%) | -$100.18 M(-4.3%) |
| June 2014 | - | -$58.40 M(-11.2%) | -$104.70 M(+313.6%) |
| Mar 2014 | - | -$65.73 M(-417.1%) | -$25.31 M(-574.0%) |
| Dec 2013 | $5.34 M(-115.4%) | $20.73 M(-1688.4%) | $5.34 M(-57.3%) |
| Sept 2013 | - | -$1.30 M(-106.2%) | $12.50 M(-48.9%) |
| June 2013 | - | $20.99 M(-159.8%) | $24.46 M(-199.3%) |
| Mar 2013 | - | -$35.08 M(-225.8%) | -$24.62 M(-29.2%) |
| Dec 2012 | -$34.76 M(+884.2%) | $27.89 M(+161.7%) | -$34.76 M(-44.9%) |
| Sept 2012 | - | $10.65 M(-137.9%) | -$63.10 M(+12.9%) |
| June 2012 | - | -$28.09 M(-37.9%) | -$55.89 M(+102.4%) |
| Mar 2012 | - | -$45.22 M(>+9900.0%) | -$27.61 M(+681.8%) |
| Dec 2011 | -$3.53 M(-93.5%) | -$451.00 K(-102.5%) | -$3.53 M(-83.9%) |
| Sept 2011 | - | $17.86 M(+9154.4%) | -$21.93 M(-62.7%) |
| June 2011 | - | $193.00 K(-100.9%) | -$58.74 M(-28.0%) |
| Mar 2011 | - | -$21.14 M(+12.1%) | -$81.56 M(+49.1%) |
| Dec 2010 | -$54.70 M | -$18.85 M(-0.5%) | -$54.70 M(+83.8%) |
| Sept 2010 | - | -$18.95 M(-16.2%) | -$29.77 M(+888.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2010 | - | -$22.63 M(-495.3%) | -$3.01 M(-114.9%) |
| Mar 2010 | - | $5.72 M(-5.9%) | $20.19 M(+67.5%) |
| Dec 2009 | $12.06 M(-72.9%) | $6.09 M(-22.0%) | $12.06 M(+10.8%) |
| Sept 2009 | - | $7.80 M(+1242.9%) | $10.88 M(+72.5%) |
| June 2009 | - | $581.00 K(-124.1%) | $6.31 M(+16.7%) |
| Mar 2009 | - | -$2.41 M(-149.1%) | $5.41 M(-87.8%) |
| Dec 2008 | $44.42 M(+113.2%) | $4.91 M(+52.0%) | $44.42 M(+34.9%) |
| Sept 2008 | - | $3.23 M(-1109.1%) | $32.93 M(-35.6%) |
| June 2008 | - | -$320.00 K(-100.9%) | $51.14 M(+16.4%) |
| Mar 2008 | - | $36.60 M(-656.4%) | $43.95 M(+110.9%) |
| Dec 2007 | $20.84 M(-82.7%) | -$6.58 M(-130.7%) | $20.84 M(-58.8%) |
| Sept 2007 | - | $21.44 M(-385.1%) | $50.58 M(-6.1%) |
| June 2007 | - | -$7.52 M(-155.7%) | $53.89 M(-27.5%) |
| Mar 2007 | - | $13.49 M(-41.7%) | $74.33 M(-38.2%) |
| Dec 2006 | $120.28 M(+1182.0%) | $23.16 M(-6.4%) | $120.28 M(+37.8%) |
| Sept 2006 | - | $24.75 M(+91.5%) | $87.31 M(+119.1%) |
| June 2006 | - | $12.93 M(-78.3%) | $39.85 M(-31.7%) |
| Mar 2006 | - | $59.44 M(-706.4%) | $58.38 M(+522.2%) |
| Dec 2005 | $9.38 M(-49.2%) | -$9.80 M(-56.8%) | $9.38 M(-62.9%) |
| Sept 2005 | - | -$22.72 M(-172.2%) | $25.31 M(-76.1%) |
| June 2005 | - | $31.46 M(+201.2%) | $105.70 M(+24.7%) |
| Mar 2005 | - | $10.44 M(+70.4%) | $84.74 M(+358.8%) |
| Dec 2004 | $18.47 M(-109.9%) | $6.13 M(-89.4%) | $18.47 M(-198.4%) |
| Sept 2004 | - | $57.67 M(+449.6%) | -$18.77 M(-89.0%) |
| June 2004 | - | $10.49 M(-118.8%) | -$170.26 M(-14.6%) |
| Mar 2004 | - | -$55.83 M(+79.4%) | -$199.34 M(+6.8%) |
| Dec 2003 | -$186.65 M(+305.6%) | -$31.11 M(-66.8%) | -$186.65 M(+35.4%) |
| Sept 2003 | - | -$93.81 M(+404.7%) | -$137.81 M(+518.4%) |
| June 2003 | - | -$18.59 M(-56.9%) | -$22.28 M(-297.2%) |
| Mar 2003 | - | -$43.13 M(-343.4%) | $11.30 M(-124.6%) |
| Dec 2002 | -$46.02 M(+176.6%) | $17.72 M(-18.4%) | -$46.02 M(-49.4%) |
| Sept 2002 | - | $21.72 M(+44.8%) | -$90.89 M(-27.1%) |
| June 2002 | - | $14.99 M(-114.9%) | -$124.66 M(-5.0%) |
| Mar 2002 | - | -$100.45 M(+269.9%) | -$131.16 M(+688.4%) |
| Dec 2001 | -$16.64 M(-78.0%) | -$27.16 M(+125.5%) | -$16.64 M(-74.4%) |
| Sept 2001 | - | -$12.04 M(-241.8%) | -$65.10 M(+48.8%) |
| June 2001 | - | $8.49 M(-39.6%) | -$43.75 M(-17.6%) |
| Mar 2001 | - | $14.07 M(-118.6%) | -$53.07 M(-29.9%) |
| Dec 2000 | -$75.67 M(+257.0%) | -$75.62 M(-912.0%) | -$75.67 M(+159.6%) |
| Sept 2000 | - | $9.31 M(-1222.0%) | -$29.15 M(-25.6%) |
| June 2000 | - | -$830.00 K(-90.3%) | -$39.17 M(+38.2%) |
| Mar 2000 | - | -$8.54 M(-70.7%) | -$28.34 M(+33.7%) |
| Dec 1999 | -$21.20 M(-551.1%) | -$29.10 M(+4057.1%) | -$21.20 M(-643.6%) |
| Sept 1999 | - | -$700.00 K(-107.0%) | $3.90 M(-61.8%) |
| June 1999 | - | $10.00 M(-814.3%) | $10.20 M(-1233.3%) |
| Mar 1999 | - | -$1.40 M(-65.0%) | -$900.00 K(-119.1%) |
| Dec 1998 | $4.70 M(-165.3%) | -$4.00 M(-171.4%) | $4.70 M(-622.2%) |
| Sept 1998 | - | $5.60 M(-609.1%) | -$900.00 K(-95.4%) |
| June 1998 | - | -$1.10 M(-126.2%) | -$19.50 M(-657.1%) |
| Mar 1998 | - | $4.20 M(-143.8%) | $3.50 M(-148.6%) |
| Dec 1997 | -$7.20 M(-85.2%) | -$9.60 M(-26.2%) | -$7.20 M(+118.2%) |
| Sept 1997 | - | -$13.00 M(-159.4%) | -$3.30 M(-17.5%) |
| June 1997 | - | $21.90 M(-436.9%) | -$4.00 M(-91.4%) |
| Mar 1997 | - | -$6.50 M(+14.0%) | -$46.60 M(-4.1%) |
| Dec 1996 | -$48.60 M | -$5.70 M(-58.4%) | -$48.60 M(+13.3%) |
| Sept 1996 | - | -$13.70 M(-33.8%) | -$42.90 M(+46.9%) |
| June 1996 | - | -$20.70 M(+143.5%) | -$29.20 M(+243.5%) |
| Mar 1996 | - | -$8.50 M | -$8.50 M |
FAQ
- What is Neurocrine Biosciences annual cash flow from investing activities?
- What is the all time high annual CFI for Neurocrine Biosciences?
- What is Neurocrine Biosciences annual CFI year-on-year change?
- What is Neurocrine Biosciences quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Neurocrine Biosciences?
- What is Neurocrine Biosciences quarterly CFI year-on-year change?
- What is Neurocrine Biosciences TTM cash flow from investing activities?
- What is the all time high TTM CFI for Neurocrine Biosciences?
- What is Neurocrine Biosciences TTM CFI year-on-year change?
What is Neurocrine Biosciences annual cash flow from investing activities?
The current annual CFI of NBIX is -$467.10 M
What is the all time high annual CFI for Neurocrine Biosciences?
Neurocrine Biosciences all-time high annual cash flow from investing activities is $120.28 M
What is Neurocrine Biosciences annual CFI year-on-year change?
Over the past year, NBIX annual cash flow from investing activities has changed by -$290.00 M (-163.75%)
What is Neurocrine Biosciences quarterly cash flow from investing activities?
The current quarterly CFI of NBIX is $24.70 M
What is the all time high quarterly CFI for Neurocrine Biosciences?
Neurocrine Biosciences all-time high quarterly cash flow from investing activities is $93.40 M
What is Neurocrine Biosciences quarterly CFI year-on-year change?
Over the past year, NBIX quarterly cash flow from investing activities has changed by +$122.00 M (+125.39%)
What is Neurocrine Biosciences TTM cash flow from investing activities?
The current TTM CFI of NBIX is -$260.30 M
What is the all time high TTM CFI for Neurocrine Biosciences?
Neurocrine Biosciences all-time high TTM cash flow from investing activities is $120.28 M
What is Neurocrine Biosciences TTM CFI year-on-year change?
Over the past year, NBIX TTM cash flow from investing activities has changed by +$120.60 M (+31.66%)